Reading Room Production — page 112

not support this legislation, we remain 5 PM [AID DEA DART ID DIR-OCGR < I I (ID DCR-OCGR ay ' TT IIAID) (NIH/NIAID) [E] P| [E] 4/NIAID) [E] I I VIH/NIAID) [I] iy >; P| (NIH/NIAID) [E] P| IIH/NIAID) [--] NIAID) [E] 'nate Committee on S is now requesting any y (9/27), ct 7PM [AID DEA DART NIAID) [E] i NIAID) [E] VIH/NIAID) [E] ii st NIH/NIAID) [E] VIH/NIAID) [E] iy >; al || (NIH/NIAID) [E] NIH/NIAID) [E] ay NIAID) [E] on public health, safety, and national security. We recommend that enforcement provisions be focused on willful violations and significantly reduced or adjusted. Given the above concerns, as drafted, this legislation has the potential to negatively impact innovation and delay the development of lifesaving technologies. While the Administration does not support this legislation, we remain committed to working with the Committee on biosafety and biosecurity. From: Crawford, Chase (NIH/NIAID) [E] Sent: Wednesday, September 25, 2024 1:45 PM To: NIAID BUGS @niaid.nih.gov>; NIAID DEA DART @mail.nih.gov>; NIAID DIR-OCGR <NIAIDDIR- @mail.nih.gov>; NIAID DCR-OCGR @mail.nih.gov>; Nealy, Michael (NIH/NIAID) [E] @nih.gov>; Auchincloss, Hugh (NIH/NIAID) [E] @niaid.nih.gov>; Harper, Jill (NIH/NIAID) [E] @niaid.nih.gov>; Parker, Marie (NIH/NIAID) [E] @niaid.nih.gov>; Billet, Courtney (NIH/NIAID) [E] @niaid.nih.gov> Cc: NIAID OCGR Leg @mail.nih.gov>; Erbelding, Emily (NIH/NIAID) [E] @nih.gov>; Holland, Steven (NIH/NIAID) [E] @niaid.nih.gov>; Hanson, Christopher (NIH/NIAID) [E] @niaid.nih.gov>; Poe, Kelly (NIH/NIAID) [E] @nih.gov>; Gilles, Sharon (NIH/NIAID) [E] @nih.gov>; DDSM Correspondences @mail.nih.gov> Subject: ACTION by COB Friday (9/27): Review revised bill text for Risky Research Review Act Good Afternoon, NIAID has been asked to review the revised bill text for the Risky Research Review Act (PDF of bill text and Word doc of the redline are attached). This morning, the attached version of the bill was reported out of the Senate Committee on Homeland Security & Governmental Affairs (HSGAC) and now awaits further Senate consideration. As you may recall, NIH and other OPDIVs provided comments on a previous version of the bill (previous NIAID comments attached for reference). HHS is now requesting any new comments that OPDIVS may have. ACTION: By COB Friday (9/27), please review the attached redline and provide any new comments directly in the document. Thanks, Chase From: Selgrade, Sara (NIH/NIAID) [E] @nih.gov> Sent: Tuesday, July 16, 2024 6:07 PM To: NIAID BUGS @niaid.nih.gov>; NIAID DEA DART @mail.nih.gov>; NIAID DIR-OCGR <NIAIDDIR- @mail.nih.gov>; Nealy, Michael (NIH/NIAID) [E] @nih.gov>; Auchincloss, Hugh (NIH/NIAID) [E] @niaid.nih.gov>; Harper, Jill (NIH/NIAID) [E] @niaid.nih.gov>; Parker, Marie (NIH/NIAID) [E] @niaid.nih.gov>; Billet, Courtney (NIH/NIAID) [E] @niaid.nih.gov> Cc: NIAID OCGR Leg @mail.nih.gov>; Erbelding, Emily (NIH/NIAID) [E] @nih.gov>; Holland, Steven (NIH/NIAID) [E] @niaid.nih.gov>; Hanson, Christopher (NIH/NIAID) [E] @niaid.nih.gov>; Poe, Kelly (NIH/NIAID) [E] @nih.gov>; Gilles, Sharon (NIH/NIAID) [E] @nih.gov>; DDSM Correspondences @mail.nih.gov> Subject: URGENT review by 8am Wed. 7/17: HHS Comments to OMB on Risky Research Review Act Importance: High Hello all,